OX40 Monoclonal Antibodies for Treatment of Canine Cancer

A dog

Available for Licensing
TRL: 4

IP Status

US Utility Patent Pending (Not Yet Published)


Steven Dow
Leone Hopkins

At A Glance

Researchers at Colorado State University have developed an immunotherapy treatment for canines suffering from osteosarcoma. This treatment involves antibodies specific for the canine OX40 molecule expressed by canine immune cells, which can then activate an immune response. Studies have shown a 60% reduction in tumor volume when using this treatment.

For more details, please contact our office!

Licensing Director

Steve Foster

Reference No.:  18-013


Osteosarcoma (OSA) is the most common primary bone tumor in dogs, accounting for 85% of all canine bone cancers. It is stimated that more than 8000 dogs are diagnosed with OSA each year in the United States (3). Curative-intent treatment of osteosarcoma aims to achieve complete tumor control of the primary bone lesion and delay or prevent the onset of metastatic disease. Treatment options with curative intent include amputation or limb-sparing surgery for local tumor control followed by adjuvant chemotherapy for systemic disease. Other treatment options include the use of immunomodulators and high-dose radiation therapy (4).

Technology Overview

The antibody developed herein targets the OX40, a glycoprotein mainly found on immune T-cells and is involved in the migration of activated T-cells into tissues following inflammatory signals. It is considered an immune checkpoint, and certain cancers develop by evading the immune system activation. Antibody activation of immune cells has shown promise for treating human and animal diseases, by stimulating an immune response from native T-cells. The OX40 antibody developed has exhibited delayed tumor growth and decreased tumor cell volume compared to a placebo group and an alternate immune checkpoint in animal models of OSA.
This technology may also prove useful in the development of immunotherapy drugs for human diseases and cancers, due to similar immune system and immune responses between dogs and humans (1). Thus, the antibody developed here may prove useful in the study of immune responses and oncology (2).

  • Specific antibody targeting the activation of immune cells reduces need for chemotherapy and radiation therapy
  • Prevents metastatic growth
  • Reduces side effects associated with current cancer treatment options
  • 60% reduction in tumor volume in animals models, compared with placebo and an alternative immune checkpoint
  • Simple administration of medication
  • Treatment of canine osteosarcoma
  • Treatment of other cancers sensitive to OX40 activation
  • Treatment of chronic infections in canines
  • Model for studying human immunotherapy and drug development

(1) Dow, Steven. “A Role for Dogs in Advancing Cancer Immunotherapy Research.” Frontiers in Immunology, vol. 10, 17 Jan. 2020, https://doi.org/10.3389/fimmu.2019.02935 .

(2) Mueller, F, et al. “Comparative Biology of Human and Canine Osteosarcoma.” Anticancer Research, vol. 27, no. 1A, Jan. 2007, https://doi.org/https://ar.iiarjournals.org/content/anticanres/27/1A/155.full.pdf.

(3) Schwartz, Anthony L., et al. “Orthotopic Model of Canine Osteosarcoma in Athymic Rats for Evaluation of Stereotactic Radiotherapy.” American Journal of Veterinary Research, vol. 74, no. 3, 2013, pp. 452–458., https://doi.org/10.2460/ajvr.74.3.452.

(4) Walter, C. U., et al. “Curative-Intent Radiation Therapy as a Treatment Modality for Appendicular and Axial Osteosarcoma: A Preliminary Retrospective Evaluation of 14 Dogs with the Disease.” Veterinary and Comparative Oncology, vol. 3, no. 1, 2005, pp. 1–7., https://doi.org/10.1111/j.1476-5810.2005.00062.x.

Last updated: April 2022

Add keywords or various names of inventors here (text is hidden)

Canine cancer, immunotherapy, osteosarcoma, cancer treatment, immunotherapy checkpoint

Boehringer Animal Health, Merck animal Health, Virbac, Elanco, Novartis Animal Health, Zoetis, Huvepharma, VetDC Inc